| Note: this medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original PMA or panel track supplement and may not represent the most recent labeling. |
| |
| Device | LIAISON® XL MUREX HBeAg, LIAISON® XL MUREX Control HBeAg |
| Generic Name | Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) |
| Regulation Number | 866.3172 |
| Applicant | DiaSorin, Inc. 1951 Northwestern Ave. Stillwater, MN 55082 |
| PMA Number | P180048 |
| Date Received | 12/14/2018 |
| Decision Date | 08/29/2020 |
| Reclassified Date | 10/20/2025 |
| Product Code |
LOM |
| Docket Number | 20M-1783 |
| Notice Date | 09/01/2020 |
| Advisory Committee |
Microbiology |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approval for the LIAISON® XL MUREX HBeAg, LIAISON® XL MUREX Control HBeAg. The LIAISON® XL MUREX HBeAg assay is an in vitro chemiluminescent immunoassay (CLIA) for the qualitative detection of hepatitis B virus (HBV) e antigen (HBeAg) in human adult and pediatric (2-21 years) serum and plasma (lithium and sodium heparin, sodium citrate and K2 EDTA), including separator tubes, on the LIAISON® XL Analyzer. Assay results in conjunction with other laboratory results and clinical information may be used as an aid in the diagnosis of hepatitis B virus (HBV) infection in patients with symptoms of hepatitis or who may be at risk for hepatitis B (HBV) infection.The assay is not intended for use in screening blood, plasma, or tissue donors.The LIAISON® XL MUREX Control HBeAg (negative and positive) is intended for use as assayed quality control samples to monitor the performance of the LIAISON® XL MUREX HBeAg assay. The performance characteristics of LIAISON® XL MUREX Control HBeAg have not been established for any other assays or instrument platforms. |
| Approval Order | Approval Order |
| Summary | Summary of Safety and Effectiveness |
| Labeling | Labeling
|
| Supplements: |
S008 S009 S002 S010 S003 S004 S005 S006 S018 S019 S011 S012 S007 S021 S017 S020 S015 S016 S014 |
|
|